Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Patients with stage I and II low grade follicular lymphoma are randomised between standard
therapy (involved field radiotherapy) and investigational therapy (involved field
radiotherapy and chemotherapy plus rituximab). The main endpoint is progression free survival
but overall survival and the influence of t(14;18) status will also be studied.
Phase:
Phase 3
Details
Lead Sponsor:
Trans Tasman Radiation Oncology Group Trans-Tasman Radiation Oncology Group (TROG)